Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: The SIOPEL group experience

European Journal of Cancer

Volumn 44, Issue 4, 2008, Pages 545-550

  De Ioris, Maretta ^a   Brugieres, Laurence ^a   Zimmermann, Arthur ^b   Keeling, Jean ^c   Brock, Penelope ^d   Maibach, Rudolf ^e   Pritchard, Jon ^c   Shafford, Liz ^f   Zsiros, Joszef ^g   Czaudzerna, Piotr ^h   Perilongo, Giorgio ⁱ  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF BERN   (Switzerland)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e Swiss Institute for Applied Cancer Research   (Switzerland)

^f UK Children's Cancer Study Group (UKCCSG)   (United Kingdom)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h MEDICAL UNIVERSITY OF GDANSK   (Poland)

ⁱ UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Alpha fetoprotein; Hepatoblastoma; Histology

Indexed keywords

ALPHA FETOPROTEIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HEPATOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL;

ALPHA-FETOPROTEINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEPATOBLASTOMA; HUMANS; INFANT; INFANT, NEWBORN; LIVER NEOPLASMS; MALE; TREATMENT OUTCOME;

EID: 40449142901     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.11.022     Document Type: Article

References (17)

1. Schnater J.M., Kohler S.E., Lamers W.H., von Schweinitz D., and Aronson D.C. Where do we stand with hepatoblastoma? A review. Cancer 98 (2003) 668-678
2. Von Schweinitz D., Hecker H., Harms D., et al. Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma - a report from the German Cooperative Pediatric Liver Tumor Study HB-89. J Pediatr Surg 30 (1995) 845-852
3. Pritchard J., Brown J., Shafford E., et al. Cisplatin, doxorubicin and delayed surgery for childhood hepatoblastoma: a successful approach - results of the first prospective study of the International Society of Paediatric Oncology. J Clin Oncol 18 (2000) 3819-3828
4. Perilongo G., Shafford E., and Plaschkes J. Liver Tumour Study Group of the International Society of Paediatric Oncology. SIOPEL trials using preoperative chemotherapy in hepatoblastoma. Lancet Oncol 1 (2000) 94-100
5. Perilongo G., Shafford E., Maibach R., et al. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology - SIOPEL 2. Eur J Cancer 40 (2004) 411-421
6. Von Schweinitz D., Hecker H., Schmidt-von-Arndt G., and Harms D. Prognostic factors and staging systems in childhood hepatoblastoma. Int J Cancer 74 (1997) 593-599
7. Brown J., Perilongo G., Shafford E., et al. Pretreatment prognostic factors for children with hepatoblastoma - results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 36 (2000) 1418-1425
8. Van Tornout J.M., Buckley J.D., Quinn J.J., et al. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children's Cancer Group. J Clin Oncol 15 (1997) 1190-1197
9. Zimmermann A. The emerging family of hepatoblastoma tumours: from ontogenesis to oncogenesis. Eur J Cancer 41 (2005) 1503-1514
10. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 53 (1959) 457-481
11. Fuchs J., Rydzynski J., Von Schweinitz D., et al. Study Committee of the Cooperative Pediatric Liver Tumor Study Hb 94 for the German Society for Pediatric Oncology and Hematology. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB94. Cancer 95 (2002) 172-182
12. Ortega J.A., Douglass E.C., Feusner J.H., et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol 18 (2000) 2665-2675
13. Jassam N., Jones C.M., Briscoe T., and Horner I J.H. The hook effect: a need for constant vigilance. Ann Clin Biochem 43 (2006) 314-317
14. Stiller C.A., Pritchard J., and Steliarova-Foucher E. Liver cancer in European children: incidence and survival, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 42 (2006) 2115-2123
15. Haas J.E., Muczynski K.A., Krailo M., et al. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer 64 (1989) 1082-1095
16. Conran R.M., Hitchcock C.L., Waclawiw M.A., Stocker J.T., and Ishak K.G. Hepatoblastoma: the prognostic significance of histologic type. Pediatr Pathol 12 (1992) 167-183
17. Haas J.E., Feusner J.H., and Finegold M.J. Small cell undifferentiated histology in hepatoblastoma may be unfavorable. Cancer 92 (2001) 3130-3134